Clinical trials: Acinetobacter Infections
Acinetobacter Baumannii Infection
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
This research project is being conducted to look at the safety, tolerability, and pharmacokinetics (PK; how the human body processes a substance) of ETX2514 when given to healthy volunteers intravenously as a single dose, and…
- Trial name
- NCT02971423
- Testing
- ETX2514, Sulbactam, Imipenem/Cilastatin
- Where
- Australia
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Entasis Therapeutics
Infection Control
Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria
The purpose of this study is to determine whether extra cleaning of frequently-contaminated surfaces in intensive care rooms is effective in preventing contamination of disposable isolation gowns and gloves with multi-drug…
- Trial name
- NCT01481935
- Testing
- Enhanced cleaning of surfaces in ICU rooms
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Maryland, Baltimore
Acinetobacter Infections
Clinical Outcomes and Global Epidemiology -Data Coordinating Center
The primary objective is to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection.
- Trial name
- NCT00524563
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Pittsburgh
Ventilation Acquired Pneumonia
Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center
The goal of this clinical trial is to determine the most effective empirical therapy of antibiotics for better ventilator-associated pneumonia control.
- Trial name
- NCT06739382
- Testing
- extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin., two β-lactam antibiotics plus a single non-β-lactam antibiotic, Control group received standard therapy
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Beni-Suef University
Infection Due to Resistant Bacteria, Pneumonia, Ventilator-Associated
Colistin and Rifampicin for MDR-Acinetobacter
Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients.
- Conditions
- Infection Due to Resistant Bacteria, Pneumonia, Ventilator-Associated, Hospital Acquired Pneumonia, Infection of Bloodstream
- Trial name
- CoRAb (NCT01577862)
- Testing
- Colistin, Rifampicin
- Volunteers
- 210 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hematological Diseases, Carbapenem-resistant Enterobacteriaceae
Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China
Carbapenem-resistant Organisms (CRO) include Carbapenem-resistant Enterobacteriaceae (CRE), Carbapenem-resistant Pseudomonas aeruginosa (CRPA) and Carbapenem-resistant Acinetobacter baumannii (CRAB).
- Conditions
- Hematological Diseases, Carbapenem-resistant Enterobacteriaceae, Carbapenem-resistant Pseudomonas Aeruginosa, Carbapenem-resistant Acinetobacter Baumannii
- Trial name
- CROSS (NCT05002582)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sir Run Run Shaw Hospital
Osteomyelitis
Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Acinetobacter baumannii is an opportunist pathogen that has become increasingly important over recent years as a cause of nosocomial infections.
- Trial name
- NCT03559530
- Testing
- Antimicrobial
- Where
- Brazil
- Volunteers
- 262 people
- Sponsor
- University of Sao Paulo
Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
- Trial name
- NCT07226557
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Acinetobacter Infections
Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients.
- Trial name
- NCT05586815
- Testing
- Colistin, Minocycline
- Where
- Thailand
- Volunteers
- 94 people
- Sponsor
- Mahidol University
Drug Safety
Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii
In Siriraj Hospital, colistin alone for treatment of MDR A. baumannii contributed to mortality 45% Fosfomycin is an antimicrobial which has activity against gram-negative bacterial including MDR A.
- Trial name
- NCT01297894
- Testing
- colistin, colistin plus fosfomycin
- Where
- Thailand
- Volunteers
- 92 people
- Sponsor
- Mahidol University
Acinetobacter Infections
Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
This study purposed to examine the adequate range of therapeutic concentration for Korean people by observing curative effects, side effects, blood concentration, etc. in treating CRAB-infected patients with colistin.
- Trial name
- NCT02482961
- Testing
- colistimethate sodium
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- DongGuk University
Pneumonia, Bloodstream Infection
Clinical Outcomes in Patients With Infection by Resistant Microorganism
The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and…
- Conditions
- Pneumonia, Bloodstream Infection, Urinary Tract Infections, Skin Infection
- Trial name
- NCT05880069
- Testing
- Pathogen resistant phenotype
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Hospital Universitario Virgen Macarena
Acinetobacter Infections
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use [4], may be transmitted from person to person [5], and may be passed via environmental contamination [6].
- Trial name
- NCT00462579
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pittsburgh
Gram-Negative Bacterial Infections
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae…
- Trial name
- NCT00079989
- Testing
- tigecycline
- Volunteers
- 115 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cross Infection, Pneumonia, Bacterial
Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii
Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii…
- Trial name
- NCT00645723
- Testing
- Colistin, Colistin and saline solution
- Where
- Spain
- Volunteers
- 67 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
Covid19, Bacteremia
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
- Conditions
- Covid19, Bacteremia, Septicemia, Acinetobacter Baumannii Infection
- Trial name
- NCT04636554
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Health Care Associated Infection, Hand Hygiene
Reducing Intraoperative Infection Transmission in the Pediatric Operating Room
Patients becoming infected during hospitalization occurs frequently and causes harm. It is important for healthcare facilities to take action to prevent these infections and their spread between patients.
- Trial name
- NCT03992209
- Testing
- Standard care, Protocolized care
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
This Phase IIb study aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam or cefiderocol in patients with suspected or confirmed CRABC infections.
- Conditions
- Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection, Meningitis, Bacterial
- Trial name
- RIV- CARE (NCT07431307)
- Testing
- BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT)
- Volunteers
- 120 people
- Sponsor
- BioVersys AG
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Infection Resistant to Drugs, Gram-Negative Bacterial Infection
Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals
This study aims to assess how large an additional disease burden and what extra costs are generated by antibiotic resistance in patients suffering from infections caused by gram-negative bacteria, such as Escherichia coli and…
- Trial name
- GRAND-ABC (NCT02007343)
- Where
- 8 sites in Netherlands
- Volunteers
- 3,895 people
- Sponsor
- UMC Utrecht